<DOC>
	<DOCNO>NCT01326858</DOCNO>
	<brief_summary>The purpose study ass ocular comfort safety olopatadine hydrochloride opthalmic solution . 0.7 % .</brief_summary>
	<brief_title>Safety Comfort AL-4943A Ophthalmic Solution</brief_title>
	<detailed_description>In 3-treatment , 3-period , 6-sequence crossover study , subject receive 3 product randomize order , 1 product time , washout period 24 hour treatment period . Following instillation study medication , subject complete 3-minute discomfort profile .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ketotifen</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Able dosed eye , follow instruction , willing able attend require study visit . Negative urine pregnancy test female childbearing potential use adequate birth control throughout study period . Other protocoldefined inclusion criterion may apply . History clinical evidence ocular herpes simplex ocular herpes zoster infectious disease . History clinically significant external ocular disease within 30 day start study . Presence active blepharitis , active meibomian gland dysfunction , active rosacea affect ocular surface/lid margin , active chronic follicular conjunctivitis , preauricular adenopathy , ocular periocular abnormality may affect study outcome . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Ocular discomfort</keyword>
	<keyword>AL-4943A Ophthalmic Solution</keyword>
</DOC>